Metabolic syndrome, prediabetes and the science of primary prevention

Minerva Endocrinologica

Volumn 36, Issue 2, 2011, Pages 129-145

  Nyenwe, E A ^a   Dagogo Jack, S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diabetes mellitus; Glucose metabolism disorders; Lifestyle

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BEZAFIBRATE; FATTY ACID; FENOFIBRATE; GEMFIBROZIL; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

BARIATRIC SURGERY; BIRTH DEFECT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; GENE INTERACTION; GENETIC ASSOCIATION; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SELF MONITORING; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT;

DISEASE PROGRESSION; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERINSULINISM; INFLAMMATION; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; PREDIABETIC STATE; PRIMARY PREVENTION;

EID: 79960622356     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. World Health Organization. 2008-2013 Action plan for the global strategy for the prevention and control of non-communicable diseases. Geneva: WHO; 2008.
2. World Health Organization. 2011 Fact sheet N 312 and 317. [cited 2011 April 5]. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/ index.html.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
4. Centers for Disease Control and Prevention 2011. Press Release January 13, 2011 [Internet]. [Accessed 2011 January 26; cited 2011 April 51. Available at: www.cdc.gov/media/release.
5. Centers for Disease Control and Prevention 2007 National diabetes fact sheet. [Accessed 2011 January 19; cited 2011 April 5]. Available at: www.cdc.gov/heartdisease
6. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121:46-e215.
7. Kylin E. Hypertonie-hyperglykamie-hyperurikamie-syndrome. Zentralblatt fur innere Medizin 1923;44.
8. Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesite. Presse Med 1947;30:339-40.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association 2004 Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551-6.
11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
13. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
14. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
15. Alberti KG, Zimmet PZ, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome- a new worldwide definition. Lancet 2005;366:1059-62.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
17. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9. (Pubitemid 34251969)
18. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33:351-75. (Pubitemid 38680634)
19. Ridker PM, Buring JE, Cook NR, Rifai N. Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
20. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-100.
21. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-S9.
23. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985;15(Suppl):41-6.
24. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
25. DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes in the DCCT/EDIC. N Engl J Med 2005;353:2643-53.
26. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-20.
27. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-55. (Pubitemid 39410805)
28. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
29. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
30. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al.; VADT Investigators glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
31. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003;52:2867-73. (Pubitemid 37466854)
32. Sullivan SD, Ratner RE. A should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011 [Epub ahead of print].
33. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137-44.
34. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010;53:600-5.
35. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181-3.
36. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
37. Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav 2006;88:234-43.
38. Sjögren M, Lyssenko V, Jonsson A, Berglund G, Nilsson P, Groop L et al. The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 2008;51:2242-51.
39. Eliasson B, Attvall S, Taskinen MR, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb 1994;14:1946-50.
40. Lakka TA, Laaksonen DE, Lakka HM, Männikkö N, Niskanen LK, Rauramaa R, Salonen JT. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 2003;35:1279-86.
41. Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J Intern Med 2011;269:127-36.
42. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
43. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54. (Pubitemid 40396812)
44. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1998;320:1060-8.
45. Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. J Biol Chem 2002;277:32915-22. (Pubitemid 34984805)
46. Befroy DE, Petersen KF, Dufour S, Mason GF, de Graaf RA, Rothman DL et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007;56:1376-81. (Pubitemid 46715630)
47. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:12587-94.
48. Shand BI, Scott RS, Lewis JG, Elder PA. Frampton CM. Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: a 3-year prospective study. Int J Obes (Lond) 2009;33:1274-9.
49. Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KG et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring) 2008;16:2707-16.
50. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94.
51. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699-713. (Pubitemid 28201798)
52. Shaper AG. Obesity and cardiovascular disease. Ciba Found Symp 1996;201:90-103; 103-7, 188-93.
53. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-8 (Pubitemid 26052915)
54. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
55. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004;110:1564-71. (Pubitemid 39297977)
56. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52:2882-7. (Pubitemid 37466856)
57. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:2970-3. (Pubitemid 32269184)
58. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;75:767-72. (Pubitemid 34250692)
59. Aljada A, Mohanty P, Ghanim H, Abdo T, Tripathy D, Chaudhuri A et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-90. (Pubitemid 41103915)
60. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-92. (Pubitemid 34925335)
61. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA) a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002;45:1609-16.
62. Giacchetti G, Faloia E, Sardu C, Camilloni MA, Mariniello B, Gatti C et al. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S142-3.
63. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2010;108:1875-81.
64. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
65. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. Clin Invest 1994;94:1172-9.
66. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87:2246-52.
67. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-55.
68. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52:2882-7. (Pubitemid 37466856)
69. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33-
70. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
71. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111:747-53. (Pubitemid 40250635)
72. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003;46:1297-312. (Pubitemid 37297198)
73. Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H et al. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J Biol Chem 2004;279:27263-71. (Pubitemid 38812565)
74. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
75. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
76. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. (Pubitemid 32378388)
77. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
78. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94. (Pubitemid 29536364)
79. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults. JAMA 2000;283:2253-9.
80. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK et al. Predictors of progression from impaired glucose tolerance to NID-DM: an analysis of six prospective studies. Diabetes 1997;46:701-10.
81. Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:305-31 (Pubitemid 38680632)
82. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398-403. (Pubitemid 37392211)
83. Junyent M, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M et al. Genetic variants at the PDZ-interacting domain of the scavenger receptor class B type I interact with diet to influence the risk of metabolic syndrome in obese men and women. J Nutr 2009;139:842-8.
84. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991;303:1019-22.
85. Bo S, Cavallo-Perin P, Scaglione L, Ciccone G, Pagano G. Low birthweight and metabolic abnormalities in twins with increased susceptibility to Type 2 diabetes mellitus. Diabet Med 2000;17:365-70.
86. Edeoga C, Dagogo-Jack S. Understanding and identifying pre-diabetes: can we halt the disease? US Endocrinology 2008;4:20-3.
87. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. Diabetologia 1991;4.891-8.
88. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
89. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
90. Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. (Pubitemid 32378388)
91. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97.
92. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888-94.
93. Dagogo-Jack S. Primary prevention of cardiovascular disease in pre-diabetes: the glass is half-full and half-empty (editorial). Diabetes Care 2005;28:971-2.
94. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J et al., Finnish Diabetes Prevention Study Group. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003;52:1872-6.
95. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR et al., Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355.241-50.
96. Moore AF, Jablonski KA, Mason CC, Mc-Ateer JB, Arakaki RF, Goldstein BJ et al., Diabetes Prevention Program Research Group. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab 2009;94:449-55.
97. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J et al. Variant of transcription factor 7-like 2 (TCF7L2J gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-3.
98. Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, Sandeep S et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 2005;54:1207-13. (Pubitemid 40446338)
99. Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007;50:2451-60.
100. Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H et al., Diabetes Prevention Program Research Group. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007;92:1502-9.
101. Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 2008;57:1419-26.
102. Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen G et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008;57:95-101.
103. Dagogo-Jack S, Egbuonu N, Edeoga C. Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract 2010;19:167-75.
104. Kriska A. Striving for a more active community: lessons from the Diabetes Prevention Program and beyond. Am J Prev Med 2002;22:6-7. (Pubitemid 34436881)
105. Zimmet P, Shaw J, Alberti KGMM. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003;20:693-702. (Pubitemid 41701460)
106. Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with lownormal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab 2009;94:2031-6.
107. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr 2004;79:31-9. (Pubitemid 41132059)
108. Kimm SY, Glynn NW, Kriska AM, Barton BA, Kronsberg SS, Daniels SR et al. Decline in physical activity in black and white girls during adolescence. N Engl J Med 2002;347:709-15.
109. Diabetes Prevention Program Research Group: The Diabetes Prevention Program, description of lifestyle intervention. Diabetes Care 2002;25:2165-71.
110. Esposito K, Pontillo A, di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
111. Butryn ML, Phelan S, Hill JO, Wing RR. Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity (Silver Spring) 2007;15:3091-6. (Pubitemid 351256672)
112. Pour OR, Dagogo-Jack S. Prediabetes as a Therapeutic Target. Clin Chem 2011;57:1-6.
113. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
114. Orgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61. (Pubitemid 38196725)
115. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C et al. Effects of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22. (Pubitemid 43343284)
116. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16.
117. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized double-blind, placebo controlled study. Int J Obes 2007;31:138-46.
118. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011;36:10-8.
119. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009;32:547-51.
120. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006;166:737-41.
121. Tenenbaum A, Motro M, Fisman EZ. Dual and panperoxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005;4:14.
122. Dagogo-Jack S. Primary prevention of type-2 diabetes in developing countries. J Natl Med Assoc 2006;98:415-9. (Pubitemid 43352534)
123. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61. (Pubitemid 47295642)
124. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52. (Pubitemid 47295641)
125. O'Brien PE, Sawyer SM, Laurie C, Brown WA, Skinner S, Veit F et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010;303:519-26.
126. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76.
127. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90.